Connect your AI

Celcuity CELC Accounts payable and other current liabilities (Note 11)

Accounts payable and other current liabilities (Note 11) at other companies

Crinetics PharmaceuticalsCRNX

——

Royalty PharmaRPRX

——

TG TherapeuticsTGTX

——

Neurocrine BiosciencesNBIX

——

Other financials

Income statement

Operating income-$50.5M-39.8%

Net income-$52.8M-42.8%

EPS (diluted)-$0.97-12.8%

Balance sheet

Cash & equivalents$145.2M+781%

Total debt$137.9M+30.7%

Total equity$53.5M-38.2%

Total assets$410.2M+88.0%

Cash flow

Operating cash flow-$55.1M-53.6%

CapEx$249.0K+315%

Free cash flow-$55.3M-54.0%

Valuation

Market cap$4.4B+1,370%

Returns & leverage

Return on equity-275.2%-990pp

Debt / equity2.6×+1.4×

Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.

The official record: Celcuity’s 10-K, filed March 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celcuity's accounts payable and other current liabilities (note 11).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Celcuity's accounts payable and other current liabilities (note 11)?: Celcuity (CELC) reported accounts payable and other current liabilities (note 11) of $0 in Q4 2025.